Literature DB >> 7911924

Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus.

T Lohmann1, R D Leslie, M Hawa, M Geysen, S Rodda, M Londei.   

Abstract

To find the dominant epitopes of a major autoantigen in insulin-dependent diabetes mellitus (IDDM), glutamic acid decarboxylase (GAD), we studied the reactivity of peripheral blood T lymphocytes with peptides covering both major isoforms. A significant response to GAD 65 or GAD 67 peptides was detected in 13 of 15 IDDM patients and in 9 of 10 normal controls. Controls most frequently recognised the central region of GAD 65 (residues 161-243). IDDM patients preferentially recognised residues 473-555 (p < 0.03). T-cell responses to GAD 67 peptides were similar in IDDM patients and controls. T lymphocytes from IDDM patients recognise a distinct dominant epitope of GAD, which may be an important target for the disease process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911924     DOI: 10.1016/s0140-6736(94)93061-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

Review 1.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha1*0101,beta1*0401) transgenic mice.

Authors:  S D Patel; A P Cope; M Congia; T T Chen; E Kim; L Fugger; D Wherrett; G Sonderstrup-McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 3.  Molecular aspects of type 1 diabetes.

Authors:  M A Kelly; M L Rayner; C H Mijovic; A H Barnett
Journal:  Mol Pathol       Date:  2003-02

4.  Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Authors:  Arno Hänninen; Merja Soilu-Hänninen; Christiane S Hampe; Angie Deptula; Kelly Geubtner; Jorma Ilonen; Mikael Knip; Helena Reijonen
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

Review 5.  T cell epitopes and post-translationally modified epitopes in type 1 diabetes.

Authors:  John W McGinty; Meghan L Marré; Veronique Bajzik; Jon D Piganelli; Eddie A James
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

6.  Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients.

Authors:  J Endl; H Otto; G Jung; B Dreisbusch; F Donie; P Stahl; R Elbracht; G Schmitz; E Meinl; M Hummel; A G Ziegler; R Wank; D J Schendel
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

7.  Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice.

Authors:  L Wen; F S Wong; L Burkly; M Altieri; C Mamalaki; D Kioussis; R A Flavell; R S Sherwin
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

8.  Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes.

Authors:  Cheuk Wun Li; Roman Osman; Francesca Menconi; Erlinda S Concepcion; Yaron Tomer
Journal:  J Autoimmun       Date:  2016-09-23       Impact factor: 7.094

9.  Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes.

Authors:  G Rudy; N Stone; L C Harrison; P G Colman; P McNair; V Brusic; M B French; M C Honeyman; B Tait; A M Lew
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

10.  Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes.

Authors:  V A L Huurman; P E van der Meide; G Duinkerken; S Willemen; I R Cohen; D Elias; B O Roep
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.